EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Y-Biologics, Inc (338840) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Y-Biologics, Inc KRW 1,029, price KRW 8,520, upside -87.9%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

YB Thin data Sep 24, 2026

Y-Biologics, Inc

338840 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,029 KRW · Strongly overvalued (−87.9%)
!Quality 20/100
!Weak Growth (revenue 3y −11.1 %/yr)
!Moderate debt · negative free cash flow
!Trails peers (1/7)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Y-Biologics, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

35,600 KRW 5,480 KRW Fair Value 1,029 KRW Dec 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

34‑month range 5,480 KRW – 35,600 KRW · fair‑value band 678.96 KRW – 1,286 KRW · the 8,520 KRW price screens above the 1,029 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Y-Biologics in your weekly email

Every Wednesday you see whether Y-Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor.

Show more

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.

Stock analysis

Y-Biologics, Inc (338840) currently trades at 8,520 KRW, while our model-based Fair Value estimate is 1,029 KRW, 87.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 678.96 KRW (bear) to 1,286 KRW (bull), the price of 8,520 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Y-Biologics, Inc reported revenue of 2.9B KRW in FY2025 versus 4.8B KRW in FY2021, a compound −12.0%/yr. Reported net income was −42.0B KRW in FY2025.

Key figures

Market cap 145B KRW (≈ $108M) · P/S ratio 51.9 · Return on equity −222% · Return on assets (EBIT) −45.9% · Operating margin −1,376% · Revenue (TTM) 2.8B KRW · Revenue growth (YoY) −30.8% · Free cash flow −7.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 76% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, 338840 screens richer than that median.

Fair Value models

Bear 678.96 KRW Fair Value 1,029 KRW Bull 1,286 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 876.18 KRW 1,174 KRW 1,752 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 876.18 KRW 1,174 KRW 1,752 KRW 54

Open the full fair value analysis →

Notify me when 338840 reaches fair value

Put 338840 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 25 · Market factors (momentum, volatility) 17

Profitability 2
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 3
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 63
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−49.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−358.2% (2021) → −318.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

338840 screens overvalued: fair value 88% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Y-Biologics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −87.9% · Bottom 25%
Profitability
Return on assets −18.5% · Below median
Growth and dividend
Revenue growth −30.8% · Bottom 25%
Balance sheet
Debt / equity 0.54× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)73 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Y-Biologics, Inc · Fair Value
1,029 KRW −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Y-Biologics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/338840

Frequently asked questions

Is Y-Biologics, Inc (338840) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,029 KRW versus a price of 8,520 KRW, about −88% upside (overvalued).
What is the fair value of 338840?
Our model-based fair value for Y-Biologics, Inc is 1,029 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,520 KRW.
What is the quality score of 338840?
Y-Biologics, Inc has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Y-Biologics, Inc (338840)?
Our model-based price target is the fair value of 1,029 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 678.96 KRW, optimistic scenario 1,286 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Y-Biologics, Inc stock forecast for 2026?
Our models put fair value at 1,029 KRW, about −88% upside versus a price of 8,520 KRW (overvalued). Cautious scenario 678.96 KRW, optimistic scenario 1,286 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Y-Biologics, Inc (338840)?
Y-Biologics, Inc reported trailing-twelve-month revenue of about 2.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Y-Biologics, Inc (338840)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Y-Biologics, Inc it is 1,029 KRW per share (as of Sep 24, 2026), against a price of 8,520 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Y-Biologics, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 338840 trades above its calculated fair value: price 8,520 KRW, fair value 1,029 KRW, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 338840?
No. The price is what the market pays today (8,520 KRW); the fair value is what the company's own numbers justify (1,029 KRW). For Y-Biologics, Inc the two are 7,491 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Y-Biologics, Inc worth?
The market values Y-Biologics, Inc at about 145B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,520 KRW; our models calculate a fair value of 1,029 KRW per share.
What do the bullish and bearish scenarios say about 338840?
Our models span a range for Y-Biologics, Inc: cautious scenario 678.96 KRW, base 1,029 KRW, optimistic 1,286 KRW per share (as of Sep 24, 2026, price 8,520 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Y-Biologics, Inc (338840)?
Balance-sheet figures for Y-Biologics, Inc (as of Sep 24, 2026): return on equity −222.0%, debt of 0.54 per unit of equity. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is 338840 from its 52-week high?
Y-Biologics, Inc trades at 8,520 KRW, about 76% below its 52-week high of 35,600 KRW and 13% above the low of 7,520 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,029 KRW is for.
Which stocks are comparable to Y-Biologics, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Y-Biologics, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 8,520 KRW, calculated fair value 1,029 KRW (−88%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 338840 calculated?
We run Y-Biologics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,029 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Y-Biologics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Y-Biologics, Inc (338840)?
The closing price on Oct 2, 2026 was 8,520 KRW. Our model-based fair value is 1,029 KRW, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Y-Biologics, Inc right now?
The price sits above even our optimistic bull case (1,286 KRW). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (678.96 KRW to 1,286 KRW) leaves room in how you read the outcome.

Key figures of Y-Biologics, Inc

How large is the market capitalisation of Y-Biologics, Inc (338840)?
The market capitalisation of Y-Biologics, Inc is 145B KRW (≈ $108M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Y-Biologics, Inc (338840)?
The price-to-sales ratio of Y-Biologics, Inc is 51.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Y-Biologics, Inc (338840)?
The return on equity (ROE) of Y-Biologics, Inc is −222% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Y-Biologics, Inc (338840)?
On an EBIT basis the return on assets of Y-Biologics, Inc is −45.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Y-Biologics, Inc (338840)?
The operating margin of Y-Biologics, Inc is −1,376% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Y-Biologics, Inc (338840)?
Revenue at Y-Biologics, Inc is growing −30.8% versus a year earlier (3y avg −11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Y-Biologics, Inc (338840) generate?
The free cash flow of Y-Biologics, Inc is −7.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Y-Biologics, Inc in the live analysis

One click puts Y-Biologics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.